Oradexon (Dexamethasone Sodium Phosphate)

The drug binds to intracellular glucocorticoid receptors, forming a complex that moves into the cell nucleus and modifies gene expression. This suppresses the production of inflammatory cytokines, reduces immune cell activation, and limits fluid accumulation, providing rapid anti‑inflammatory and immunosuppressive effects.

The specific dose and administration schedule are determined by the prescribing clinician based on the patient’s condition, severity, and response. Dosing may vary widely, and the prescriber will tailor the regimen to individual therapeutic needs.

Corticosteroids cross the placenta and are excreted in breast milk. Use during pregnancy or lactation should only occur when the potential benefit outweighs the risk, and it must be decided by a qualified healthcare professional after careful evaluation.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed), and required import documentation.

Oradexon delivers dexamethasone sodium phosphate, a potent, water‑soluble glucocorticoid with rapid onset when given intravenously or intramuscularly. Compared with longer‑acting agents like methylprednisolone, dexamethasone offers stronger anti‑inflammatory potency per milligram but may require closer monitoring of glucose and electrolytes.

Oradexon should be stored refrigerated between 2 °C and 8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain sterility and potency.

The product is supplied as a sterile injectable solution and is administered by a healthcare professional via intravenous infusion or intramuscular injection, following aseptic technique and appropriate dosing guidelines established by the prescriber.

Serious risks include severe hyperglycemia, opportunistic infections, adrenal insufficiency on abrupt discontinuation, and rare but critical complications such as osteonecrosis or psychiatric disturbances. Patients should be monitored closely for these events, especially during high‑dose or prolonged therapy.

Individuals with known hypersensitivity to dexamethasone or any component of the formulation should avoid Oradexon. It is also contraindicated in patients with systemic fungal infections that require systemic therapy, unless the benefits clearly outweigh the risks.